openPR Logo
Press release

Patent Expiries To Drive Growth Of The Global Antidiabetic Biosimilars Market

03-30-2018 09:43 AM CET | Health & Medicine

Press release from: Pharmaceutical Report

Patent Expiries To Drive Growth Of The Global Antidiabetic

Antidiabetic biosimilars market overview

Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and clinical testing to demonstrate that the biosimilar developed provides the same therapeutic benefit to patients as the reference product.

Get The Holistic SAMPLE With Research Methodology:
https://www.coherentmarketinsights.com/insight/request-sample/92

Patent expiries to drive growth of the global antidiabetic biosimilars market

The global antidiabetic biosimilars market is driven by increasing number of diabetes mellitus patients. According to World Health Organization (WHO) the number of people suffering from diabetes stood at 422 million in 2014. The global prevalence of diabetes among adults above 18 years increased to 8.5% in 2014 from 4.7% in 1980. Increasing incidence of lifestyle disorders such as obesity, increases the risk of diabetes and in turn drives growth of the antidiabetic biosimilars market. In June 2014, the European Medicines Agency authorized the first biosimilar of insulin Glargine, Abasaglar from Eli Lilly and Company and Boehringer Ingelhim International Gmbh, for treatment of diabetes mellitus. The biosimilar received U.S. FDA approval in 2016, which would fuel growth of the antidiabetic biosimilars market.

Furthermore patent expiry of insulin aspart and insulin lispro is projected to propel growth of antidiabetic biosimilars market. Biosimilar insulin have potential to reduce diabetes treatment costs, increase accessibility of insulin treatment and expand the number of insulin brands.

Constraints for growth of the antidiabetic biosimilars market

Biosimilars would have to face stringent regulatory requirements that would focus on their production before entering into major markets such as the U.S. While biosimilars have marked successful entry in the European markets, entry in the U.S. market is still a challenge due to stringent regulatory norms. Furthermore, biosimilars would need to gain favorable reimbursement to gain market traction.


Increasing number of diabetes patients driving the antidiabetic biosimilars market globally

Increasing incidence of diabetes, complexities in alternative diabetic therapies, and government incentives for introduction of low cost therapies are collectively creating a conducive environment for growth of the market. According to the International Diabetes Federation (IDF), there were around 59.8 million diabetic patients in Europe in 2015. The market for antidiabetic biosimilar is expected to be high in near future in Asia Pacific due to increase in research activities related to antidiabetic products and supportive government funding. North America region is projected to represent a lucrative market for antidiabetic biosimilar in the near future, as prevalence of diabetes is increasing in this region. According to the International Diabetes Federation, in 2015, over 29.1 million people in the U.S. suffered from diabetes.

Get Table Of Content:
https://www.coherentmarketinsights.com/ongoing-insight/toc/92

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Patent Expiries To Drive Growth Of The Global Antidiabetic Biosimilars Market here

News-ID: 998910 • Views: 276

More Releases from Pharmaceutical Report

Batten Disease Treatment Market - Global Industry Insights, Trends, Outlook, and …
Batten disease is a rare, inherent, and fatal autosomal recessive neural disorder that begins in the childhood but may take a few years to show symptoms. Batten disease is one of the approximately 50 diseases that fall under the category of lysosome shortage disorders. The batten disease also referred as Neuronal ceroid Lipofuscinoses (NCLs), which is a class of life-limiting genetic neurogenerative diseases that are caused due to abnormality of
Opioids – Reducing body pain but increasing pain for regulatory authorities
Opioids are drugs primarily prescribed for pain management and treatment of diarrhea and cough. Opioid drugs are of two types namely, agonist and antagonist. Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, and Oxymorphone are classified as agonists, while Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, and Nalbuphine are classified as antagonists. Due to easy availability of opioids, these drugs are rampantly overused globally and the situation is more critical in
Human Chorionic Gonadotropin (HCG) Market to Rear Excessive Growth During 2016 …
Human chorionic gonadotropin hormone (HCG) is a hormone secreted by the placenta after implantation of a fertilized zygote in the uterus. The hormone also supports normal development of an egg and helps in the stimulation of egg release from the ovary. The HCG is mainly used to induce ovulation in the women under infertility treatment. It is also used among males mostly to increase the sperm count and in young
Medical Waste Management Market, By Services, and By Techniques - Global Industr …
Healthcare activities generates a lot of waste, especially from the frequently used consumables, which are harmful for in-patients and healthy population. Medical waste includes waste generated within research centers and health-care facilities for example, sharps waste, infectious waste, pathological waste, pharmaceutical waste, chemical waste, and radioactive waste. The waste product that are generated by the healthcare activities have higher potential to spread infection and injuries. Inadequate or incorrect handling of

All 5 Releases


More Releases for Antidiabetic

Antidiabetic Biosimilars Market Regional Landscape, Status and Prospects 2020-20 …
Antidiabetic Biosimilars Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Antidiabetic Biosimilars industry overview and then goes into each and every detail. Antidiabetic Biosimilars Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Antidiabetic Biosimilars also provides data about the company and its operations. This report also provides information on the
Global Antidiabetic Biguanides Sales Market Advanced Technologies and Developmen …
Qyresearchreports include new market research report "Global Antidiabetic Biguanides Sales Market Report 2017" to its huge collection of research reports. This report on the global Antidiabetic Biguanides market has been developed by a selected group of professional market research analysts, with a solitary goal to present the existing scenario of the market for Antidiabetic Biguanides and shed light on its growth prospects. The report targets audiences such as manufacturers of Antidiabetic
Antidiabetic Biosimilars Market Expected to Grow Globally
Antidiabetic biosimilars market overview Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and
03-07-2017 | Health & Medicine
SA-BRC
Antidiabetic Drugs Market and Pipeline Assessment
Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment
Global Antidiabetic Thiazolidinediones Market Research Report 2017
The research report on the global Antidiabetic Thiazolidinediones market studies the market in the past based on which estimates are presented for the future. The report looks into vital market indicators, trends, and opportunities that will have a bearing on the development of this market. The report begins with an outline of terms and terminologies, classifications, and applications that are standard conventions in the global Antidiabetic Thiazolidinediones market. A glance into
Antidiabetic Biosimilars Market, Company Analysis and Forecast to 2024
Antidiabetic biosimilars market overview Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and